Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ray Borrow

Showing results (371-380 of 403) with videos related to

Pageof 41
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2015
Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of AgeMilagritos D Tapia, Helen Findlow, Olubukola T Idoko, et al.
The Lancet. Child & Adolescent Health|March 19, 2021
SARS-CoV-2 infection and transmission in primary schools in England in June-December, 2020 (sKIDs): an active, prospective surveillance studyShamez N Ladhani, Frances Baawuah, Joanne Beckmann, et al.
Vaccine|September 18, 2025
Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlersAbraham Hodgson, Fadima Cheick Haidara, Samba O Sow, et al.
Vaccine|January 22, 2019
Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwideAlessandro Muzzi, Alessandro Brozzi, Laura Serino, et al.
The Journal of Infection|October 22, 2023
Meningococcal disease in the Middle East: A report from the Global Meningococcal InitiativeSeif S Al-Abri, Musallam Yunus Abuhasan, Soha Shawqi A Albayat, et al.
The New England Journal of Medicine|June 17, 2011
Immunogenicity and safety of a meningococcal A conjugate vaccine in AfricansSamba O Sow, Brown J Okoko, Aldiouma Diallo, et al.
Eclinicalmedicine|October 5, 2021
Antibody persistence and neutralising activity in primary school students and staff: Prospective active surveillance, June to December 2020, EnglandGeorgina Ireland, Anna Jeffery-Smith, Maria Zambon, et al.
Expert Review of Vaccines|December 12, 2018
The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populationsReinaldo Acevedo, Xilian Bai, Ray Borrow, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2015
Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 YearsAldiouma Diallo, Samba O Sow, Olubukola T Idoko, et al.
Mbio|March 15, 2018
Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic VaccineLisa K McNeil, Robert G K Donald, Alexey Gribenko, et al.
Pageof 41

Showing results (371-380 of 403) with videos related to

Sort By:
Pageof 41
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2015
Antibody Persistence 1-5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12-23 Months of AgeMilagritos D Tapia, Helen Findlow, Olubukola T Idoko, et al.
The Lancet. Child & Adolescent Health|March 19, 2021
SARS-CoV-2 infection and transmission in primary schools in England in June-December, 2020 (sKIDs): an active, prospective surveillance studyShamez N Ladhani, Frances Baawuah, Joanne Beckmann, et al.
Vaccine|September 18, 2025
Immunogenicity and safety of a meningococcal a conjugate vaccine administered with routine EPI vaccines in African infants and toddlersAbraham Hodgson, Fadima Cheick Haidara, Samba O Sow, et al.
Vaccine|January 22, 2019
Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwideAlessandro Muzzi, Alessandro Brozzi, Laura Serino, et al.
The Journal of Infection|October 22, 2023
Meningococcal disease in the Middle East: A report from the Global Meningococcal InitiativeSeif S Al-Abri, Musallam Yunus Abuhasan, Soha Shawqi A Albayat, et al.
The New England Journal of Medicine|June 17, 2011
Immunogenicity and safety of a meningococcal A conjugate vaccine in AfricansSamba O Sow, Brown J Okoko, Aldiouma Diallo, et al.
Eclinicalmedicine|October 5, 2021
Antibody persistence and neutralising activity in primary school students and staff: Prospective active surveillance, June to December 2020, EnglandGeorgina Ireland, Anna Jeffery-Smith, Maria Zambon, et al.
Expert Review of Vaccines|December 12, 2018
The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: Epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populationsReinaldo Acevedo, Xilian Bai, Ray Borrow, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2015
Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 YearsAldiouma Diallo, Samba O Sow, Olubukola T Idoko, et al.
Mbio|March 15, 2018
Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic VaccineLisa K McNeil, Robert G K Donald, Alexey Gribenko, et al.
Pageof 41